Neurocardiogenic syncope medical treatment

Neurocardiogenic Syncope Microchapters

Home

Patient Info

Overview

Pathophysiology

Epidemiology and Demographics

Risk Factors

Causes

Natural History, Complications & Prognosis

Differentiating Neurocardiogenic Syncope From Other Diseases

Diagnosis

History & Symptoms

Physical Examination

Tilt Table Testing

Treatment

Pharmacotherapy

Pacemaker therapy

Neurocardiogenic syncope medical treatment On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neurocardiogenic syncope medical treatment

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neurocardiogenic syncope medical treatment

CDC on Neurocardiogenic syncope medical treatment

Neurocardiogenic syncope medical treatment in the news

Blogs on Neurocardiogenic syncope medical treatment

Directions to Hospitals Treating Neurocardiogenic Syncope

Risk calculators and risk factors for Neurocardiogenic syncope medical treatment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Treatment

[edit | edit source]

* Infrequent episodes of vasovagal syncope that are preceded by a warning prodrome probably do not require any intervention besides counseling and observation. Attention to hydration and salt intake may suffice.

* Beta blockers are preferred as initial treatment but have not been demonstrated as effective in a randomized clinical trial. The Prevention of Syncope Trial showed that metoprolol was overall ineffective in preventing syncope.

* In patients with borderline low blood pressure who may be subject to symptomatic orthostasis, fludrocortisone, midodrine, and compression hose are often used initially.
* Midodrine (ProAmantine 2.5-10 TID), an alpha agonist has been shown to be effective in several randomized controlled clinical trials. Side effects include nausea and supine hypertension.
* Fludrocortisone 0.1 mg/ Day, a mineralocorticoid that promotes renal reabsorption of sodium to cause increased blood volume has been used in the treatment of vasodepressor syncope in both children and adults. Caution is needed in elderly patients because they poorly tolerate the drug and there is a risk of hypertension, cardiac failure, and edema.

* Scopolamine, an anticholinergic agent, has central nervous system depressant effects and has been used successfully in some patients with syncope.

* Selective serotonin reuptake inhibitors (Paxil 20mg/ Day) selectively block serotonin, which has been shown to induce vagally mediated bradycardia and blood pressure lowering.

* Pyridostigmine (Mestinon 60mg po BID), an acetylcholinesterase inhibitor which increases acetylcholine levels at the autonomic ganglia. It prevents a drop in blood pressure without causing supine hypertension. Demonstrated to be effective in POTS and orthostatic hypotension. Can be used in conjuction with Midrodrine.

* In regards to pacing, in the VPS II Study, 100 patients whoo were > 19 years of age who had a history of recurrent vasovagal syncope with 6 episodes of syncope ever or 3 episodes in the past 2 years, and a positive result on the head-up tilt table test (TTT) with a heart rate × blood pressure product < 6000/min × mm Hg were randomized to receive dual chamber pacing with rate drop. The results demonstrated that fewer patients in the DDD group than the ODO group had syncope during follow-up, but the difference did not reach statistical significance. Compared with ODO, the relative risk reduction in time to syncope with DDD was 30% (95% CI −33% to 63%). The number of pacemaker complications was similar between the DDD and ODO groups (10 vs 9 complications).

## References

[edit | edit source]

Template:WikiDoc Sources